Full Press Release Details
Lexaria Announces Human Clinical Study on CBD Absorption
Kelowna, British Columbia April 23, 2018 Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery
platform innovator, is pleased to announce that it has commenced a clinical
study in Europe to evaluate the cardiovascular and cognitive health effects of
Lexaria s high absorption TurboCBD capsules.
The pharmacokinetic and pharmacodynamic data generated by this
study will provide objective human performance findings that will assist in the
development of the Company s next-generation cannabinoid product formulations
and be of significant benefit to the Company and its partners.
The study employs a double-blind and placebo-controlled
cross-over design measuring TurboCBD effects both after a single 45mg dose and,
on a separate day, after a single 90mg dose in 12 healthy male volunteers. The
study hypothesises that, following TurboCBD supplementation, circulating CBD
and nitric oxide will increase in most participants; that glucose and blood
pressure will remain stable; and that vascular function, and cognitive
performance will improve. The same DehydraTECHTM technology is being
used to deliver CBD in this human study, as was used by the Company in its
recent rodent-based nicotine absorption study, illustrating the wide
applicability of the Company s patented drug delivery platform.
This advanced study will utilize the latest clinical evaluation
techniques to provide pharma-level pharmacokinetic and pharmacodynamic
performance data of TurboCBD , including blood sampling, physiological measures,
cognitive function testing and cardiovascular function testing. Outcome
measurements will include circulating CBD and nitric oxide markers, plasma
glucose, plasma insulin, blood pressure, heart rate, respiration, peripheral and
brain blood flow and a battery of neuropsychological performance tests.
This study was originally intended to be conducted at the
University of British Columbia but policy change has resulted in a move to a
medical university in Europe, where it is presently being conducted. Study
results are expected within 90 days. Depending on results, a second phase
clinical study in elderly is already designed and has received necessary
regulatory approvals and could commence later in 2018.
Breakthrough Nicotine Absorption Results To Be Presented
Tomorrow in Atlanta, GA. Separately, Lexaria announces that it is presenting the
results of its recent breakthrough nicotine absorption study at the Next
Generation Nicotine Delivery 2018 USA conference April 24th & 25th 2018,
in Atlanta, USA. The Company has two prominent speaking appointments to present
their latest ingestible nicotine absorption breakthrough: Link
To an audience of big tobacco players and regulatory
representatives, Lexaria is presenting the only truly novel and unique approach
to new nicotine product delivery in the industry today.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECHTM delivery technology. Lexaria s technology provides
increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For regular updates, connect with Lexaria on Twitter
and on Facebook http://tinyurl.com/y8vzcaam
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation
and regulatory approvals, managing and maintaining growth, the effect of adverse
publicity, litigation, competition, scientific discovery, the patent application
and approval process and other factors which may be identified from time to time
in the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance the Company will be capable
of developing, marketing, licensing, or selling edible products containing
cannabinoids, nicotine or any other active ingredient. There is no assurance
that any planned corporate activity, scientific research or study, business
venture, technology licensing pursuit, patent application or allowance, consumer
study, or any initiative will be pursued, or if pursued, will be successful.
There is no assurance that any of Lexaria s postulated uses, benefits, or
advantages for the patented and patent-pending technology will in fact be realized in any manner or in
any part. No statement herein has been evaluated by the Food and Drug
Administration (FDA). Lexaria-associated products are not intended to diagnose,
treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.